5-[1-(2-ethoxyphenyl)sulfonylazetidin-3-yl]-3-thiophen-3-yl-1,2,4-oxadiazole Usage And Synthesis

Uses

VU0531245 is a SLACK channel inhibitor (IC50: 2.1 μM)[1].

References

[1] Qunies AM, et al. Design, synthesis, and biological evaluation of a novel series of 1,2,4-oxadiazole inhibitors of SLACK potassium channels: Identification of in vitro tool VU0935685. Bioorg Med Chem. 2023 Sep 30;95:117487. DOI:10.1016/j.bmc.2023.117487

5-[1-(2-ethoxyphenyl)sulfonylazetidin-3-yl]-3-thiophen-3-yl-1,2,4-oxadiazole(1396749-92-0)Related Product Information

• VU 0463841
• [Hexahydro-5-(4-pyridinyl)pyrrolo[3,4-c]pyrrol-2(1H)-yl][1-(5-isoquinolinylsulfonyl)-3-azetidinyl]-Methanone
• N-(5-chloro-2-methoxyphenyl)-2-[4-(4-methylpiperidin-1-yl)sulfonylpiperazin-1-yl]acetamide
• VU0453595
• VU 0364439
• VU 0360223
• 2(5H)-Furanone, 3-(3-fluorophenyl)-4-(4-methoxyphenyl)-
• VU 0360172
• cyclopentyl 1,6-dimethyl-4-(6-nitro-1,3-benzodioxol-5-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
• N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide
• (1R,2R)-N-([S]-1-{4-[5-broMo-2-oxo-2,3-dihydro-1H-benzo(d)iMidazol-1-yl]piperidin-1-yl}propan-2-yl)-2-phenylcyclopropanecarboxaMide
• Urea, N-(3,4-difluorophenyl)-N'-[3-methyl-1-(phenylmethyl)-1H-pyrazol-5-yl]-
• VU-0486321
• VU0238441
• VU0483605
• VU0453379
• VU0810464
• VU-0410150